{
  "id": "58848822e56acf517600000c",
  "type": "summary",
  "question": "What is the mechanism of action of Osimertinib?",
  "ideal_answer": "Osimertinib is a third-generation irreversible tyrosine kinase inhibitor of both activating EGFR mutations and resistance-associated T790M point mutation.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27861144",
    "http://www.ncbi.nlm.nih.gov/pubmed/27393507",
    "http://www.ncbi.nlm.nih.gov/pubmed/27923714",
    "http://www.ncbi.nlm.nih.gov/pubmed/26902828",
    "http://www.ncbi.nlm.nih.gov/pubmed/27169328",
    "http://www.ncbi.nlm.nih.gov/pubmed/27835594",
    "http://www.ncbi.nlm.nih.gov/pubmed/27912836",
    "http://www.ncbi.nlm.nih.gov/pubmed/26620497",
    "http://www.ncbi.nlm.nih.gov/pubmed/27885838",
    "http://www.ncbi.nlm.nih.gov/pubmed/27196753",
    "http://www.ncbi.nlm.nih.gov/pubmed/26515464",
    "http://www.ncbi.nlm.nih.gov/pubmed/27660466",
    "http://www.ncbi.nlm.nih.gov/pubmed/27071706",
    "http://www.ncbi.nlm.nih.gov/pubmed/27649127",
    "http://www.ncbi.nlm.nih.gov/pubmed/26720671",
    "http://www.ncbi.nlm.nih.gov/pubmed/26898616",
    "http://www.ncbi.nlm.nih.gov/pubmed/26943236"
  ],
  "snippets": [
    {
      "text": "In addition, mutations leading to resistance to first-line EGFR and ALK TKIs can now be successfully inhibited by soon to be approved third-generation EGFR TKIs (osimertinib, rociletinib) and second-generation ALK TKIs (ceritinib, alectinib). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26620497",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Gefitinib, erlotinib, and afatinib are the EGFR tyrosine kinase inhibitors that are presently in clinical use. Understanding resistance mechanisms has led to the identification of a secondary mutational target, T790M, in more than half of patients, for which osimertinib has been approved. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27912836",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Third-generation EGFR TKIs against the T790M mutation have been in active clinical development. These agents include osimertinib, rociletinib, HM61713, ASP8273, EGF816, and PF-06747775. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27071706",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE: Osimertinib (AZD9291) 80\u00a0mg once daily is approved by the US FDA for the treatment of patients with metastatic EGFR T790M-positive NSCLC whose disease has previously progressed on EGFR-TKI therapy. Osimertinib PK was evaluated to define the dose and dosing interval, whether a fixed-dosing approach can be used globally, and the impact of formulation and food on exposure.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902828",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RECENT FINDINGS: Third-generation TKIs in clinical development include osimertinib, rociletinib, and HM61713.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26720671",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this study, we investigated the interaction between ABCB1 and osimertinib, a novel selective, irreversible third-generation EGFR TKI that has recently been approved by the U.S. Food and Drug Administration. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27169328",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Considering that osimertinib is a clinically approved third-generation EGFR TKI, our findings suggest that a combination therapy with osimertinib and conventional anticancer drugs may be beneficial to patients with MDR tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27169328",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In our study, we investigated whether osimertinib (AZD9291), a third-generation irreversible tyrosine kinase inhibitor of both activating EGFR mutations and resistance-associated T790M point mutation, could reverse MDR induced by ABCB1 and ABCG2 in vitro, in vivo, and ex vivo Our results showed that osimertinib significantly increased the sensitivity of ABCB1- and ABCG2-overexpressing cells to their substrate chemotherapeutic agents in vitro and in the model of ABCB1-overexpressing KBv200 cell xenograft in nude mice. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27196753",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The potency of 1st (erlotinib), 2nd (afatinib) and 3rd (osimertinib and rociletinib) generation EGFR-TKIs was compared in vitro for human lung cancer cell lines and Ba/F3 cells, which exogenously express mutated or wild type EGFR",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26515464",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Osimertinib (AZD9291, Tagrisso\u2122), an oral, third-generation EGFR TKI, has been designed to target the EGFR T790M mutation, while sparing wild-type EGFR.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27660466",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Early phase clinical data suggest the third generation EGFR TKIs such as osimertinib, rociletinib, and HM61713 are highly efficacious and well tolerated.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26898616",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We review the rapid clinical development and approval of the third-generation EGFR TKI osimertinib for treatment of NSCLCs with EGFR-T790M.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26943236",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020228",
    "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D045504"
  ]
}